PD-1/PD-L1 axis is a major immune checkpoint important in the prognosis of several solid tumors (melanoma, hepatocellular carcinoma, and more recently HNSCC) (21–24) and is being clinically targeted for immunotherapy (25–29). This evidence concerns the gene CD274 and melanoma.